Prosecution Insights
Last updated: November 12, 2026
Application No. 18/684,974

AN IMPROVED PROCESS FOR THE PREPARATION OF N-ETHYL- A -METHYL-3-(TRIFLUOROMETHYL) PHENETHYLAMINE HYDROCHLORIDE

Non-Final OA §102§103§112
Filed
Feb 20, 2024
Priority
Aug 19, 2021 — IN 202141037571 +1 more
Examiner
CUTLIFF, YATE KAI RENE
Art Unit
1692
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BIOPHORE INDIA PHARMACEUTICALS PVT. LTD.
OA Round
1 (Non-Final)
80%
Grant Probability
Favorable
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allowance Rate
1044 granted / 1307 resolved
+19.9% vs TC avg
Strong +24% interview lift
Without
With
+24.2%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
42 currently pending
Career history
1346
Total Applications
across all art units

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims Claims 12 – 21 are pending. Claims 1 – 11 have been cancelled. Claim 1 is objected. Claims 12 – 21 are rejected. Claim Objections Claim 1 is objected to because of the following informalities: in step “ii” after formula (4) appears to be missing; and in step “iii” after formula (2) appears to be missing. Both instances appear to be typographical error. The numbering of claims is not in accordance with 37 CFR 1.126 which requires the original numbering of the claims to be preserved throughout the prosecution. When claims are canceled, the remaining claims must not be renumbered. When new claims are presented, they must be numbered consecutively beginning with the number next following the highest numbered claims previously presented (whether entered or not). Misnumbered the second number 14 and the claims that follow have been renumbered 15 (14), 16 (15), 17(16), 18(17), 19(18), 20(19), 21(20) and 22(21). The numbers in parenthesis are the original claim numbers. Additonally, applicant is required to correct the dependency of the newly numbered claims. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claims 13, 14, 16(15), 17(16) and 19(18) is rejected under 35 U.S.C. 112(b), as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, regards as the invention. Clams 13 and 14 recite the limitation “cooling to a suitable temperate”. The phrasing is a term of degree and is not provided with some stand for measuring that degree. The range in temperature is not clearly defined in those claims. For this reason the claim lack clarity and is indefinite. Claim 19(18) recites the limitation "the reducing agent" in line 1. There is insufficient antecedent basis for this limitation in the claim. Claim 19(18) in line3 recites the trademark/trade name "Raney". Where a trademark or trade name is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph. See Ex parte Simpson, 218 USPQ 1020 (Bd. App. 1982). The claim scope is uncertain since the trademark or trade name cannot be used properly to identify any particular material or product. A trademark or trade name is used to identify a source of goods, and not the goods themselves. Thus, a trademark or trade name does not identify or describe the goods associated with the trademark or trade name. In the present case, the trademark/trade name is used to identify/describe a type of catalyst and, accordingly, the identification/description is indefinite. Claims 16(15 and 17(16) are rejected for being dependent upon rejected base claim. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 22(21) is rejected under 35 U.S.C. 102(a)(1) & (a)(2) as being anticipated by Londesbrough, et al. WO2017/112702(A). The rejected claim cover, inter alia, A compound fenfluramine hydrochloride is having a purity of at least 99.5% by HPLC. However, Londesbrough discloses that their method produces the fenfluramine hydrochloride with a purity of 99.5%. (pp. 11, [0043] & pp. 35, Table 1C). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 12 , 13 and 15(14), 16(15) and 18(17) – 22(21) are rejected under 35 U.S.C. 103 as being unpatentable over Londesbrough, et al. WO2017/112702(A). The rejected clams cover, inter alia, a method for the preparation of fenfluramine hydrochloride of formula (1) according to the following reaction scheme. PNG media_image1.png 266 574 media_image1.png Greyscale . Wherein (5) is reacted with sodium nitrite or nitrous acid to obtain (4), and aminating (2) with ethyl amine to obtain crude (1a). Dependent 13 claim further limits the purification process. Dependent clams 15(14) and 16(15) further limit the solvent. Dependent clams 18(17) and 19(18) further limit the reaction process. Dependent claim 20(19) further limits the product. Dependent claims 21(20) further limits the compound of formula (5). HoweveHowever, Londesbrough discloses in Example 5 (pp. 48 -49), a process for the preparation of fenfluramine hydrochloride comprising the steps of (i) reacting 3-trifluoromethylaniline with sodium nitrite, HX (X= Cl-) to obtain diazonium intermediate (compound of formula (4) of the instant application); (ii) reacting the said diazonium intermediate with isopropenyl acetate in presence of CuCl and NaOAc to obtain ZX008 ketone (compound of formula (2) of the instant application) ; (iii) aminating the said ketone with ethylamine to obtain Fenfluramine hydrochloride crude (pp. 34 [00120]) and (iv) crystallization of said crude to obtain pure Fenfluramine hydrochloride (pp. 36, [00124], [00125]). Also, Londesbrough discloses that their method produces the fenfluramine hydrochloride with a purity of 99.5%. (pp. 11, [0043] & pp. 35, Table 1C). The difference between Londesbrough and the claimed invention is that it does not teach the invention with particularity so as to amount to anticipation (See M.P.E.P. §2131: "[t]he identical invention must be shown in as complete detail as is contained in the ...claim." Richardson v. Suzuki Motor Co., 868 F.2d 1226, 1236, 9 USPQ2d 1913, 1920 (Fed. Cir. 1989). The elements must be arranged as required by the claim, but this is not an ipsissimis verbis test, i.e., identity of terminology is not required. In re Bond, 910 F.2d 831, 15 USPQ2d 1566 (Fed. Cir. 1990).). However, based on the above, Londesbrough teaches the elements of the claimed invention with sufficient guidance, particularity, and with a reasonable expectation of success, that the invention would be prima facie obvious to one of ordinary skill (the prior art reference teaches or suggests all the claim limitations with a reasonable expectation of success. (see M.P.E.P. § 2143). Claim Rejections - 35 USC § 103 Claim(s) 14 and 17 (16) are rejected under 35 U.S.C. 103 as being unpatentable over Londesbrough, et al. WO2017/112702(A). The rejected clam covers, inter alia, a process for purifying 3-trifluoromethylaniline hydrochloride, comprising: A. dissolving crude 3-trifluoromethylaniline in a suitable solvent; B. adding hydrochloric acid to the reaction mass; C. dissolving 3-trifluoromethylaniline hydrochloride in suitable solvent; D. cooling to suitable temperature; and E. isolating 3-trifluormethylaniline hydrochloride. Dependent claim 17(16) further limits the solvent. However, even though Londesbrough does not teach or suggest purification of 3-trifluormethylaniline hydrochloride, the prior art discloses the method for the purification of fenfluramine hydrochloride. In Londesbrough purification of fenfluramine hydrochloride is by crystallization ([00124], [00125]) comprising the steps of dissolving fenfluramine hydrochloride crude in a solvent, heating the suspension, cooling the suspension and isolating the desired compound. It would have been obvious to one of ordinary skill in the art before the effective filing date of the instantly claimed invention to purify the 3-trifluormethylaniline hydrochloride by methods like those taught in the purification of fenfluramine. Motivation for early purification of a starting reactant is found in the teaching of Londesbrough. In the disclosure there is discussion on eliminating isomers (e.g., a regioisomers) by-product of the 3-trifluormethylaniline starting material. The reason is that such by-products can be carried through synthetic steps, and be difficult to substantially eliminate from downstream compositions. (pp. 18, [0062]). Further stating, removing impurities and/or undesirable isomers early in a synthesis can be preferred, especially if such impurities are carried through to final product compositions, as purification of a final product at the end of a synthesis is more costly (e.g., in losses of valuable product) and impacts cost of goods more greatly than removing such minor components early in synthesis before raw materials are invested along the process. (pp. 18, [0062]). Therefore, all the claimed elements were known in the prior art and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions, and the combination would have yielded predictable results to one of ordinary skill in the art before the effective filing date of the instantly claimed invention. KSR International Co. v. Teleflex Inc., 550 U.S. 398, 82 USPQ2d 1385 (U.S. 2007). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to YATE' K. CUTLIFF whose telephone number is (571)272-9067. The examiner can normally be reached Monday-Friday (8:30 - 5:30). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Y. Goon can be reached at (571) 270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /YATE' K CUTLIFF/Primary Examiner, Art Unit 1692
Read full office action

Prosecution Timeline

Feb 20, 2024
Application Filed
Aug 10, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780767
METHOD FOR PRODUCING HALOGENOBICYCLO[1.1.1]PENTANE
2y 9m to grant Granted Nov 03, 2026
Patent 12759963
METHOD FOR PREPARING GLYCOLIC ACID THROUGH HYDROLYSIS OF ALKOXYACETATE
3y 2m to grant Granted Oct 13, 2026
Patent 12759955
PROCESS FOR SYNTHESISING METHANOL
3y 2m to grant Granted Oct 13, 2026
Patent 12759967
Process for Preparing Substituted Biphenyls via Suzuki Coupling of Aryl-Chlorides
2y 11m to grant Granted Oct 13, 2026
Patent 12753141
CATALYTIC AND CONTINUOUS THERMOCHEMICAL PROCESS OF PRODUCTION OF VALUABLE DERIVATIVES FROM ORGANIC MATERIALS AND/OR WASTE
3y 10m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
80%
Grant Probability
99%
With Interview (+24.2%)
Low
PTA Risk
Based on 1307 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month